imatinib amomed 100 mg
amomed pharma gmbh - imatinib - 44 - cytostatica
atosiban pharmidea 37,5 mg/5 ml infúzny koncentrát
sia pharmidea, lotyšsko - atozibán - 34 - antihormona
atosiban pharmidea 6,75 mg/0,9 ml injekčný roztok
sia pharmidea, lotyšsko - atozibán - 34 - antihormona
kostya 0,02 mg/0,075 mg obalené tablety
gedeon richter plc., maďarsko - gestodén a etinylestradiol - 17 - anticoncipientia
biseptol 100 mg/20 mg
adamed pharma s.a., poľsko - sulfametoxazol a trimetoprim - 42 - chemotherapeutica (vratane tuberkulostatik)
crealb 200 g/l infúzny roztok
sanquin plasma products b.v, holandsko - albumín - 75 - substitutio sanguinis (a krvnÉ derivÁty)
crealb 40 g/l infúzny roztok
sanquin plasma products b.v, holandsko - albumín - 75 - substitutio sanguinis (a krvnÉ derivÁty)
vinpocetine covex s.a. 10 mg tablety
covex s.a., Španielsko - vinpocetín - 83 - vasodilatantia
vinpocetine covex s.a. 5 mg tablety
covex s.a., Španielsko - vinpocetín - 83 - vasodilatantia
pemazyre
incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastické činidlá - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.